Nextcure Stock Price, News & Analysis

NextCure, Inc. (Nasdaq: NXTC) announced the appointment of Dr. Ellen G. Feigal and Dr. Anne Borgman to its Board of Directors, bringing extensive experience in clinical and biopharmaceutical sectors. This change follows the resignation of Dr. Stella Xu. Dr. Feigal specializes in biologics and oncology, while Dr. Borgman has leadership experience in hematology and oncology drug development. Both appointments aim to support NextCure's ongoing clinical programs and the advancement of new immunomedicines for cancer treatment.

NextCure (Nasdaq: NXTC) announced new data presentation from clinical studies on NC318 and NC410 at the Society for Immunotherapy of Cancer meeting from November 10-14, 2021. NC318 targets Siglec-15 to treat advanced solid tumors, while NC410 is focused on blocking LAIR-1 to enhance immune response. Oral presentations will highlight NC318’s clinical benefits, with poster sessions discussing NC410’s safety, tolerability, and immune modulation. Both drugs aim to address unmet needs in cancer therapy, showcasing NextCure's potential in developing innovative immunomedicines.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical firm, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th. The presentation will be pre-recorded and available via an audio webcast on the company’s website, with replays accessible for 30 days post-event. NextCure is focused on developing novel immunomedicines aimed at treating cancer and immune-related diseases, particularly for patients not responding to current therapies. Their proprietary FIND-IO™ platform facilitates research into immune cell targets.

NextCure, a clinical-stage biopharmaceutical company focused on developing novel immunomedicines for cancer, announced its participation in the 19th Annual Morgan Stanley Global Healthcare Conference on September 9th at 12:30 PM ET. Investors can access a live audio webcast on NextCure's website, with a replay available for 30 days post-event. The company uses its FIND-IO™ platform to discover immune cell targets, aiming to provide new therapies for patients unresponsive to current treatments.

NextCure, Inc. (Nasdaq: NXTC) reported its Q2 2021 financial results, showcasing progress in clinical trials, including the NC318 Phase 2 monotherapy trial. Key updates include resumed enrollment in NSCLC adenocarcinoma and a revised dosing regimen aimed at enhancing drug exposure. Financially, cash and equivalents decreased to $249.5 million, while net loss rose to $18.0 million due to increased operational costs. The company anticipates data updates from ongoing trials and expects its funds to last through the second half of 2023.

NextCure, Inc. (Nasdaq: NXTC) has commenced a Phase 1/2 clinical trial for NC762, a humanized B7-H4 monoclonal antibody targeting advanced solid tumors. Michael Richman, CEO, affirmed this trial extends their innovative immunomedicine pipeline for cancers inadequately treated by existing therapies. The trial evaluates NC762's safety and tolerability, with initial data expected by mid-2022. NC762 aims to inhibit tumor growth through a unique mechanism, with applications across several cancer types, including non-small cell lung cancer.

NextCure has published preclinical data on NC410, a novel immunomedicine targeting collagen-rich tumors, in the journal eLife. This treatment, currently in a Phase 1/2 clinical trial for advanced solid tumors, aims to block immune suppression via LAIR-1. Preclinical studies show that NC410 promotes T cell activity and may be effective as a monotherapy or in combination with checkpoint inhibitors. Initial clinical data is expected in the second half of 2021, offering potential hope for patients with resistant cancers.

NextCure, Inc. (Nasdaq: NXTC) announced its participation in a fireside chat at the JMP Securities Life Sciences Conference on June 17 at 1:30 pm Eastern time. Interested investors can access the live audio webcast on its website, with a replay available afterward for 30 days. NextCure is focused on developing first-in-class immunomedicines to treat cancer and other immune-related diseases through its proprietary FIND-IO™ platform, aiming to provide new treatments for patients resistant to current therapies.

NextCure, a clinical-stage biopharmaceutical company, announced that Dr. Martin Gutierrez will present a Trials in Progress poster for NC410 at the 2021 ASCO Annual Meeting. NC410 targets collagen-rich areas in tumors, acting as a LAIR-1 decoy to enhance immune responses. Preliminary studies indicate significant anti-tumor activity across multiple cancer types, including gastric and ovarian cancers. The Phase 1/2 study aims to assess safety and preliminary efficacy, with initial clinical data expected in late 2021.